In part 2 of this Exclusive Interview about the new diabetes classification, Dr. Stanley Schwartz explains the necessity of treating beta cell dysfunction even as early as prediabetes, but also needing health organizations to agree on the early use of certain treatments.
A transcript of this interview is available. Click here to read.
Stanley Schwartz, MD, Emeritus Associate Professor of Medicine at the University of Pennsylvania, has been awarded the honor of being a TOP DOC by Philadelphia Magazine many times over the years, including 2009, 2010 and 2011 for the treatment of diabetes and metabolic syndrome. For over 30 years, Dr. Schwartz was an Associate Professor at the University of Pennsylvania, most recently directing the Diabetes Program at the Philadelphia Heart Institute. Dr. Schwartz actively lectures nationally as well as internationally about diabetes and its treatment. He has authored numerous articles in peer-reviewed scientific journals and has been a lead or co-investigator for many clinical trials.
Diabetes In Control is honored to also have Dr. Schwartz on our Advisory Board as well as a frequent contributor to our newsletters. You can find all of Dr. Schwartz’s Diabetes In Control articles here
Stanley Schwartz, MD, FACP, FACE